13:05:22 EST Mon 16 Nov 2026
Enter Symbol
or Name
USA
CA



Vaso Corporation Announces Financial Results for Third Quarter of 2026

2026-11-16 09:00 ET - News Release

PLAINVIEW, N.Y., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Vaso Corporation (“Vaso”) (OTCQX: VASO), a leading MedTech company with a business portfolio in professional sales services and proprietary non-invasive medical products, today announced its operating results for the three months ended September 30, 2026.

“For the third quarter of 2026, the Company recorded net income of $568 thousand on total revenue of $10.8 million, as compared to net income of $1.7 million on total revenue of $11.4 million for the same quarter of the prior year, with healthcare IT and network services businesses excluded from both periods, as we divested the two businesses in November 2025 and July 2026, respectively,” commented Dr. Jun Ma, President and Chief Executive Officer of Vaso Corporation. “Also, when excluding the IT segment, gross profit for the quarter was $8.6 million, a decrease of $599 thousand, or 6.5%, year over year, mainly as a result of lower revenue.”

“Cash generated from operating activities for the first nine months of 2026 was $6.5 million,” Dr. Ma continued. “Total deferred revenue was $41.5 million at the end of the third quarter of 2026, an increase of $2.1 million, or 5.4%, from September 30, 2025.”

“With the completion of the Company’s exit from the network and IT services business in the third quarter of 2026, the Company now continues to operate in the professional sales service segment and proprietary medical device segment. We anticipate higher efficiency and profitability going forward as the Company can better focus its resources on the development of its businesses in the healthcare sector,” concluded Dr. Ma.

During the second quarter of 2026, the Company determined that the network service business of NetWolves met the criteria to be classified as a discontinued operation, and, as a result, NetWolves’ historical financial results are reflected in the Company’s condensed consolidated financial statements as discontinued operations, and its assets and liabilities were retrospectively reclassified as assets and liabilities held for sale.   Accordingly, the following presentation excludes NetWolves’ network service operations from current and historical results. Because the healthcare IT business sold in November 2025 was not classified as discontinued operations, the historical financial results continue to include VHC-IT’s healthcare IT operations.

Financial Results for Three Months Ended September 30, 2026

For the three months ended September 30, 2026, revenue decreased by 12.9%, to $10.8 million, from $12.4 million for the same period of 2025, mainly due to revenue decreases in the professional sales services segment and in the IT segment as a result of the divestiture of the healthcare IT business in November 2025. Revenue in the professional sales services segment in the third quarter of 2026 was down by $672 thousand, or 6.2%, year-over-year, due to lower deliveries of underlying equipment by our partner during the period as well as a lower blended commission rate applicable to such deliveries. Revenue in our equipment segment for the third quarter of 2026 increased by $19 thousand, or 3.1%, when compared to the third quarter of 2025, principally due to higher ARCS subscription revenues in our US operations, partially offset by lower equipment deliveries in our China operations. Revenue in our IT segment decreased by $938 thousand in the third quarter of 2026 when compared to the same quarter of 2025, as a result of the sale of the healthcare IT business in November 2025.

Gross profit for the third quarter of 2026 decreased by $986 thousand, or 10.3%, to $8.6 million, compared with a gross profit of $9.6 million for the same quarter of 2025, as a result of lower revenue, slightly offset by higher gross margin.

Selling, general and administrative (SG&A) expenses for the third quarter of 2026 decreased by $328 thousand, or 4.1%, to $7.7 million, compared to the third quarter of 2025. The decrease was due to reduced costs resulting from the sale of VHC-IT in November 2025 and a decrease in personnel cost in the equipment segment, partially offset by higher travel cost in the professional sales service segment as well as higher corporate SG&A expenses due to higher director fees and insurance costs.

Operating income for the three months ended September 30, 2026 was $632 thousand, compared to operating income of $1.4 million in the third quarter of 2025. The decrease of $748 thousand was primarily due to lower gross profit partially offset by lower SG&A expenses as discussed above.

Net income from continuing operations for the three months ended September 30, 2026 was $568 thousand, compared to net income from continuing operations of $1.6 million in the third quarter of 2025, a decrease of $985 thousand.

Adjusted EBITDA (earnings before interest, taxes, depreciation and amortization, and stock-based compensation) from continuing operations was $691 thousand in the third quarter of 2026 compared to $1.3 million for the third quarter of 2025, a decrease of $641 thousand. The decrease was primarily the result of lower net income and a larger income tax expense in the third quarter of 2026. Adjusted EBITDA is a non-GAAP financial metric. A reconciliation of Adjusted EBITDA from continuing operations to net income from continuing operations can be found below.

Net cash provided by operating activities was $6.5 million for the first nine months of 2026, compared to net cash provided by operating activities of $9.0 million for the first nine months of 2025. As of November 12, 2026, the Company’s cash, cash equivalents and restricted cash totaled approximately $53.3 million.

About Vaso

Vaso Corporation (OTCQX: VASO), headquartered in Plainview, New York, is a diversified healthcare-focused organization operating through wholly owned subsidiaries VasoHealthcare and VasoMedical. VasoHealthcare is the professional sales service arm for GE HealthCare’s diagnostic imaging and ultrasound products. VasoMedical designs and manufactures proprietary medical products, including Biox series non-invasive devices for recording and analysis of physiological signals, and develops and operates the ARCS cloud-based SaaS platform for cardiac telemetry.

For additional information, please visit www.vasocorporation.com or contact us at info@vasocorporation.com.

Non-GAAP Financial Information Reconciliation

We utilize Adjusted EBITDA to evaluate our performance internally, and this non-GAAP financial measure is frequently used by securities analysts, investors and other interested parties in the evaluation of companies in the Company’s industry. Management believes that this non-GAAP financial measure, in addition to GAAP measures, is useful to investors to evaluate the Company’s results.

Adjusted EBITDA is a non-GAAP financial measure and should not be considered a substitute for net income, which we consider to be the most directly comparable U.S. GAAP measure. Adjusted EBITDA has limitations as an analytical tool, and when assessing our operating performance, you should not consider Adjusted EBITDA in isolation, or as a substitute for net income or other consolidated income statement data prepared in accordance with U.S. GAAP. Investors should recognize that the Company’s presentation of this non-GAAP financial measure might not be comparable to similarly titled measures of other companies, limiting its usefulness as a comparative measure.

Summarized financial information including a reconciliation of net income from continuing operations to Adjusted EBITDA from continuing operations is set forth below:

 FOR THE THREE MONTHS ENDEDFOR THE NINE MONTHS ENDED
STATEMENTS OF OPERATIONS
 September 30, 2026
  September 30, 2025
  September 30, 2026
  September 30, 2025
 
 (In thousands)
 (unaudited)
Revenue$10,786 $12,377 $31,767 $32,841 
Gross profit 8,564  9,550  24,974  25,128 
Operating income 632  1,380  552  862 
Other (expense) income, net 299  198  756  629 
Income before taxes 931  1,578  1,308  1,491 
Income tax expense (363) (25) (625) (80)
Net income from continuing operations$568 $1,553 $683 $1,411 
Income tax expense 363  25  625  80 
Interest expense (income), net (391) (308) (930) (836)
Depreciation and amortization 123  54  357  180 
Non-cash stock-based compensation 28  8  47  24 
Adjusted EBITDA from continuing operations*$691 $1,332 $782 $859 
 
*Adjusted EBITDA is earnings (loss) before interest, taxes, depreciation and amortization and non-cash stock-based compensation
 


BALANCE SHEETS September 30, 2026
December 31, 2025
  (In thousands)
  (unaudited) 
Total current assets$65,572$58,560
Total assets$82,997$89,319
Total current liabilities$29,186$36,846
Total stockholders' equity$30,909$29,429
     

The information contained in this report contains forward-looking statements (as such term is defined in the Securities Exchange Act of 1934 and the regulations thereunder). These forward-looking statements may include projections of, or guidance on, the Company’s future financial performance, expected levels of future revenue and expenses, anticipated growth strategies, and anticipated trends in the Company’s business or financial results. When used in this report, words such as “anticipates”, “continue”, “believes”, “could”, “estimates”, “expects”, “may”, “plans”, “potential”, “future”, “intends”, the negative of these terms and similar expressions identify forward-looking statements. Any forward-looking statement made by the Company in this document is based only on the Company’s current expectations, estimates and projections about future events and financial trends affecting the financial condition of its business based on information currently available to the Company and speaks only as of the date when made. Forward-looking statements are not historical facts or guarantees of future performance. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict, many of which are outside of the Company’s control. Actual results may differ materially from this forward-looking information and therefore should not be unduly relied upon. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions, including the possibility of a downturn or disruptions in the U.S. economy; the impact of US tariff policies; the effect of the dramatic changes taking place in IT and healthcare; continuation of the GEHC agreement; the impact of competitive technology and products and their pricing; medical insurance reimbursement policies; unexpected manufacturing or supplier problems; unforeseen difficulties and delays in product development programs; the actions of regulatory authorities and third-party payers in the United States and overseas; and the risk factors reported from time to time in the Company’s SEC reports. The Company undertakes no obligation to update forward-looking statements as a result of future events or developments.

Investor Contact:
Jonathan Newton
Investor Relations Phone: 516-997-4600
Email: jnewton@vasocorporation.com


Primary Logo

© 2026 Canjex Publishing Ltd. All rights reserved.